Revvity Inc. (NYSE:RVTY – Free Report) – Research analysts at Zacks Research reduced their Q1 2028 earnings per share estimates for Revvity in a report released on Wednesday, October 28th. Zacks Research analyst Team now expects that the company will post earnings of $1.34 per share for the quarter, down from their previous forecast of $1.35. Zacks Research has a “Hold” rating on the stock. The consensus estimate for Revvity’s current full-year earnings is $5.36 per share. Zacks Research also issued estimates for Revvity’s Q2 2028 earnings at $1.63 EPS, Q3 2028 earnings at $1.62 EPS and FY2028 earnings at $6.51 EPS.
RVTY has been the subject of several other reports. Barclays raised their target price on Revvity from $115.00 to $160.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 7th. Royal Bank Of Canada initiated coverage on shares of Revvity in a report on Tuesday, September 1st. They issued a “sector perform” rating and a $135.00 price target on the stock. UBS Group assumed coverage on shares of Revvity in a research note on Wednesday, September 9th. They issued a “neutral” rating and a $140.00 price objective for the company. KeyCorp raised their price objective on shares of Revvity from $125.00 to $165.00 and gave the stock an “overweight” rating in a report on Friday, September 4th. Finally, Evercore restated an “outperform” rating on shares of Revvity in a research report on Wednesday, August 5th. Five research analysts have rated the stock with a Buy rating and thirteen have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $124.43.
View Our Latest Analysis on RVTY
Revvity Price Performance
Shares of NYSE:RVTY opened at $163.55 on Monday. The firm has a market capitalization of $18.25 billion, a PE ratio of 28.34, a PEG ratio of 2.76 and a beta of 1.08. The company has a current ratio of 1.80, a quick ratio of 1.50 and a debt-to-equity ratio of 0.36. Revvity has a 1-year low of $81.22 and a 1-year high of $171.74. The business’s 50 day moving average is $145.89 and its 200-day moving average is $112.62.
Revvity (NYSE:RVTY – Get Free Report) last announced its quarterly earnings data on Tuesday, November 3rd. The company reported $1.38 EPS for the quarter, topping analysts’ consensus estimates of $1.30 by $0.08. Revvity had a return on equity of 8.34% and a net margin of 8.16%. The company had revenue of $728.90 million during the quarter, compared to the consensus estimate of $694.73 million. During the same quarter last year, the company earned $1.18 EPS. The company’s quarterly revenue was up 4.3% on a year-over-year basis.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently modified their holdings of the business. Ascentis Independent Advisors acquired a new stake in Revvity during the 1st quarter valued at $29,000. Pillar Financial Advisors LLC bought a new position in Revvity in the 3rd quarter valued at $29,000. Heritage Family Offices LLP bought a new position in Revvity in the 3rd quarter valued at $37,000. Global Retirement Partners LLC bought a new position in Revvity in the 2nd quarter valued at $51,000. Finally, Summit Securities Group LLC boosted its stake in Revvity by 294.6% in the first quarter. Summit Securities Group LLC now owns 663 shares of the company’s stock worth $58,000 after purchasing an additional 495 shares in the last quarter. 86.65% of the stock is owned by institutional investors and hedge funds.
Insider Transactions at Revvity
In other Revvity news, insider Maxwell Krakowiak sold 1,631 shares of the business’s stock in a transaction dated Monday, September 21st. The shares were sold at an average price of $144.53, for a total value of $235,728.43. Following the transaction, the insider directly owned 14,781 shares in the company, valued at $2,136,297.93. The trade was a 9.94% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Tajinder S. Vohra sold 7,330 shares of the company’s stock in a transaction dated Wednesday, September 16th. The stock was sold at an average price of $140.88, for a total transaction of $1,032,650.40. Following the sale, the insider directly owned 6,635 shares in the company, valued at $934,738.80. This represents a 52.49% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 9,045 shares of company stock valued at $1,281,439 in the last quarter. 0.85% of the stock is currently owned by corporate insiders.
Revvity Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Friday, February 12th. Investors of record on Friday, January 22nd will be given a dividend of $0.07 per share. The ex-dividend date is Friday, January 22nd. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.2%. Revvity’s dividend payout ratio (DPR) is 13.33%.
More Revvity News
Here are the key news stories impacting Revvity this week:
- Positive Sentiment: Revvity reported adjusted earnings of $1.38 per share, ahead of analyst estimates of about $1.30, and revenue of $728.9 million, above expectations of roughly $694.7 million. Revenue increased 4.3% year over year. Revvity Q3 2026 results
- Positive Sentiment: The company raised its 2026 outlook, with reports citing Life Sciences strength and margin expansion as contributors. The improved guidance suggests management sees momentum extending beyond the reported quarter. Zacks report on results and outlook
- Neutral Sentiment: GAAP earnings per share from continuing operations were $0.56, up from $0.41 a year earlier; revenue rose from $699 million to $729 million. The year-over-year growth is positive, though revenue growth remained moderate. Company earnings release
Revvity Company Profile
Revvity, Inc provides technology, products and services for the life sciences and diagnostics markets. The company supports pharmaceutical and biotechnology research, clinical laboratories and other healthcare organizations with tools used in drug discovery, biological research, disease detection and laboratory testing.
Its offerings include laboratory instruments, reagents, consumables, software and workflow solutions. Key areas include genomics, proteomics, cellular analysis, imaging, screening, automation and reproductive health, as well as newborn screening and other diagnostic applications.
Read More
- Five stocks we like better than Revvity
- Marriott’s Earnings Beat Shows Why It’s More Than a Bet on Travel Demand
- Franklin Templeton’s New ETFs Turn Stock Dividends Into Bitcoin—What’s the Catch?
- Apple’s Earnings Beat Comes With a Catch for Investors Heading Into the Holidays
- Palantir’s $2.3 Billion Quarter Puts Its Premium Valuation to the Test
Receive News & Ratings for Revvity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revvity and related companies with MarketBeat.com's FREE daily email newsletter.
